The 8-aminoquinoline antimalarials, the only drugs which prevent relapse of vivax and ovale malaria (radical cure), cause dose-dependent oxidant haemolysis in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Patients with <30% and <70% of normal G6PD activity are not given standard regimens of primaquine and tafenoquine, respectively. Both drugs are currently considered contraindicated in pregnant and lactating women.
- Publication status:
- Peer review status:
- Peer reviewed
- Publisher's version
- Public Library of Science Publisher's website
- PLoS Neglected Tropical Diseases Journal website
- Publication date:
- Acceptance date:
- Pubs id:
- Local pid:
- Copyright holder:
- Watson et al.
- Copyright date:
Copyright © 2018 Watson et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Implications of current therapeutic restrictions for primaquine and tafenoquine in the radical cure of vivax malaria
If you are the owner of this record, you can report an update to it here: Report update to this record